Inhibikase Therapeutics (NASDAQ:IKT) Upgraded at LADENBURG THALM/SH SH

Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by stock analysts at LADENBURG THALM/SH SH to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

A number of other analysts have also issued reports on the stock. Oppenheimer assumed coverage on shares of Inhibikase Therapeutics in a research note on Wednesday, June 10th. They set an “outperform” rating and a $5.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Tuesday, April 21st. Four equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $5.40.

Inhibikase Therapeutics Trading Down 3.9%

IKT stock opened at $1.96 on Monday. The company has a market capitalization of $258.78 million, a PE ratio of -4.56 and a beta of 0.94. Inhibikase Therapeutics has a 12-month low of $1.33 and a 12-month high of $2.26. The business’s fifty day moving average price is $1.82 and its 200 day moving average price is $1.80.

Inhibikase Therapeutics (NASDAQ:IKT) last posted its earnings results on Tuesday, May 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). Research analysts predict that Inhibikase Therapeutics will post -0.4 EPS for the current fiscal year.

Institutional Investors Weigh In On Inhibikase Therapeutics

Large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its holdings in Inhibikase Therapeutics by 70.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,640 shares of the company’s stock worth $25,000 after purchasing an additional 6,458 shares during the period. SG Americas Securities LLC purchased a new position in shares of Inhibikase Therapeutics in the 1st quarter valued at about $26,000. Sanctuary Advisors LLC purchased a new position in shares of Inhibikase Therapeutics in the 4th quarter valued at about $26,000. Renaissance Technologies LLC acquired a new position in shares of Inhibikase Therapeutics during the first quarter worth about $28,000. Finally, XTX Topco Ltd acquired a new position in shares of Inhibikase Therapeutics during the fourth quarter worth about $42,000. Hedge funds and other institutional investors own 3.81% of the company’s stock.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.